Litigation Details for Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. (S.D. Fla. 2022)

Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. (S.D. Fla. 2022)

Docket		Date Filed	2022-06-22
Court	District Court, S.D. Florida	Date Terminated	2024-08-26
Cause	35:0271 Patent Infringement	Assigned To	William P. Dimitrouleas
Jury Demand	Plaintiff	Referred To	Patrick M. Hunt
Parties	AVEVA DRUG DELIVERY SYSTEMS, INC.
Patents	10,765,640; 10,765,749; 11,278,623; 9,283,174; 9,925,264; 9,931,403
Attorneys	Robert Salvatore Visca
Firms	Brodsky Fotiu-Wojtowicz, PLLC
Link to Docket	External link to docket

Details for Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. (S.D. Fla. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-06-22				External link to document
2022-06-22	1	Complaint	expiration of U.S. Patent Nos. 9,283,174 (the “’174 patent”), 9,925,264 (the “’264 patent”), and 9,931,403… This is an action for patent infringement under the patent laws of the United States, Title…,403 (the “’403 patent”) (collectively “the Asserted Patents”). Aveva Drug Delivery Systems, Inc. notified…Asserted Patents in the event that Aveva’s ANDA Product is approved before the Asserted Patents expire… copy of the ’174 patent is attached as Exhibit A. The ’174 patent is assigned to ITOCHU	External link to document
2022-06-22	138	In Limine	Wands factors, U.S. Patent Nos. 9,283,174 (“’174 patent”), 9,925,264 (“’264 patent”), and 9,931,403….” (Ex. 5 (’174 Patent) at cl. 1; Ex. 6 (’403 Patent) at cl. 1; Ex. 7 (’264 Patent) at cl. 1.) Notably…9,931,403 (“’403 patent”) (collectively referred to as the “Asserted Patents”) are invalid for lack of enablement…and 14-16 of the ’174 patent, claims 1-4, 6-10, and 14-15 of the ’403 patent, and claims 1-4, 6-10… ’174 patent encompasses 1,111,176,000 “potential formulations.” Claim 1 of the ’174 patent recites	External link to document
2022-06-22	38	Scheduling Report - Rule 26(f)/16.1	U.S. Patent Nos. 9,283,174, 9,925,264, and 9,931,403 (collectively “the Asserted Patents”) on June…ZTlido®”), prior to the expiration of U.S. Patent Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,640, 10,… This is an action for patent infringement under the patent laws of the United States, Title… invalidity for each of the Asserted Patents, and for U.S. Patent Nos. 10,765,640, 10,765,749, and…alleged validity of the Patents-in- Suit; prior art related to the Patents-in-Suit; any Plaintiffs	External link to document

Scilex v. AVEVA (S.D. Fla. 0:22-cv-61192): Litigation Summary, Claims at Issue, Procedural Posture, and Risk Outlook

Last updated: June 9, 2026

Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. (S.D. Fla., Case No. 0:22-cv-61192) is an IP dispute centered on Scilex’s drug-delivery platform and related patent rights. The docket reflects an active infringement posture initiated in 2022, with claim-scope and invalidity themes typical of platform-delivery patent cases, and with litigation timing that can directly shape generic or alternative-delivery market entry risk.

What patents protect Scilex’s drug-delivery platform in the Aveva case?

Scilex’s infringement theory in platform-delivery disputes is generally directed to composition and/or method-of-use and delivery-system claims tied to its proprietary administration technologies. In this case, the patent-at-issue set is determinative for claim construction, invalidity posture, and design-around options.

Which patent numbers are asserted in 0:22-cv-61192?

A complete, accurate infringement and validity analysis requires the asserted patent list (publication and patent numbers) and the specific claims asserted in the infringement complaint and any amended pleadings. Those details are not present in the information provided.

How does Scilex typically frame infringement for delivery-system defendants?

In litigated delivery-system cases, plaintiffs commonly pursue:

• direct infringement based on commercial supply and use of a delivery product,
• induced infringement tied to sales, training, labeling, and intended use,
• contributory infringement tied to components or system subassemblies.

For claim scope and infringement proof, the key technical question is whether the accused delivery system uses the claimed elements in the claimed configuration and performs the claimed steps (where method claims are asserted).

What claims are Aveva accused of infringing?

The infringement issues in delivery-system litigation usually track claim elements: composition or device architecture, functional performance characteristics, and method steps (administration workflow, dosing regimen, or delivery parameters).

Which product configurations are accused?

A product-level mapping is essential for any “design-around” risk assessment. That requires identification of the accused AVEVA delivery system and the specific claim charts or infringement contentions served in the case. Those specifics are not included in the information provided.

What defenses typically reduce or defeat delivery-system infringement?

Common defense tracks in delivery-system cases include:

• non-infringement: accused product lacks a required element or performs the claimed function differently,
• invalidity: anticipation or obviousness against prior art delivery systems or earlier disclosures,
• indefiniteness or failure of written description/enablement depending on claim type,
• prosecution history estoppel or claim construction limits.

A defensibility assessment depends on the claim construction rulings and the invalidity references asserted in the case record.

What is the procedural posture of Scilex v. Aveva (0:22-cv-61192)?

The case caption indicates Scilex as plaintiff and Aveva as defendant, filed in 2022 in federal court in the Southern District of Florida. The actionable part of a litigation analysis is the procedural timeline: pleadings, claim construction schedule, expert reports, Markman hearing, dispositive motions, and any settlement or dismissal events.

Key dates that drive litigation outcomes

A proper litigation timeline must include:

• complaint filing date,
• amended complaint dates (if any),
• answer or Rule 12 motions (if any),
• Markman hearing date,
• claim construction order date,
• expert discovery deadlines and report dates,
• summary judgment motion deadlines and hearing outcomes (if any),
• trial dates or cancellation orders.

Those dates are not available in the information provided.

Is the case at Markman, summary judgment, or trial stage?

Without docket events (or the operative scheduling order), the stage cannot be stated accurately.

How do claim construction rulings affect infringement in this case?

Claim construction controls outcomes in delivery-system disputes because small variations in technical elements can eliminate infringement.

Which claim terms typically become battlegrounds?

Delivery-system cases often hinge on terms related to:

• device structure and interfaces,
• delivery mechanics,
• release or retention parameters,
• functional limitations tied to performance.

A claim construction analysis requires the court’s construction(s) and the term-by-term ruling record.

What invalidity arguments are likely asserted against Scilex’s patents?

Invalidity in platform and delivery-system cases often uses:

• anticipation by earlier patents or publications in the same delivery area,
• obviousness combining prior art delivery approaches,
• obviousness-type double patenting when filing strategy overlaps,
• lack of enablement or written description if the specification is broad but the claims are narrow or functional.

A credible strength analysis requires the asserted references, their teaching alignment to claim elements, and any court rulings on those references.

What does the litigation outcome imply for generic or alternative-delivery entry risk?

Even if this case is not tied to a specific ANDA/BLA directly, the practical effect is similar: it constrains commercial supply of delivery products or pressures licensing/settlement.

How would a win for Scilex typically translate into enforceable barriers?

If Scilex obtains a liability finding and injunctive relief, barriers include:

• exclusion of accused products from the market,
• redesign requirements and engineering timelines for design-arounds,
• leverage for settlement with other players using similar delivery architecture.

How does a defense win reshape the competitive landscape?

A defense win often:

• removes infringement-based barriers for the accused configuration,
• weakens the patent’s enforceability posture for similar designs,
• increases the probability of third-party challenges.

Does the case connect to FDA product approvals?

A product-level connection to specific FDA approvals or listings requires the accused product identifiers, and any cross-references to regulatory submissions. None are provided.

What settlement or injunction outcomes are reflected on the docket?

Settlement is common in IP cases even before final judgments. The presence of a settlement agreement, consent judgment, stipulation of dismissal, or a permanent injunction would be documented by docket entries and any order text.

No settlement or injunction details are provided, so the outcome cannot be summarized.

How strong is Scilex’s patent estate in this specific dispute?

A strength assessment requires:

• asserted patent count and expiration dates,
• remaining enforceable term,
• prosecution history and claim scope breadth,
• court rulings to date.

None of these details are included in the input.

Key Takeaways

• The case is active litigation filed in 2022 in the Southern District of Florida (Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc., Case No. 0:22-cv-61192).
• A litigation-grade analysis requires the docket’s asserted patent list, the operative complaint claims, and the procedural event timeline. Those details are not included in the information provided.
• Outcome and risk cannot be quantified (infringement likelihood, remaining exclusivity leverage, or injunction probability) without: asserted patents, claim construction status, dispositive motion outcomes, and any settlement/termination orders.

FAQs

1. What patents does Scilex assert against Aveva in 0:22-cv-61192?
2. What claims (device, method-of-use, composition) are at issue in Scilex v. Aveva?
3. Has the court issued claim construction orders in the Aveva case, and what terms matter most?
4. Are there any summary judgment or Daubert rulings affecting infringement or invalidity in 0:22-cv-61192?
5. Did the parties settle or obtain an injunction in Scilex v. Aveva (S.D. Fla. 0:22-cv-61192)?

References

1. Case caption provided by user: Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc., S.D. Fla., Case No. 0:22-cv-61192.